Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G Kees

Showing results (101-110 of 376) with videos related to

Pageof 38
Sort By:
Frontiers in Pharmacology|March 8, 2021
Neurocognitive Impairment After Propofol With Relevance for Neurosurgical Patients and Awake Craniotomies-A Prospective Observational StudyNina Zech, Milena Seemann, Ralf Luerding, et al.
Expert Review of Clinical Immunology|February 25, 2022
Interleukin 6 in diabetes, chronic kidney disease, and cardiovascular disease: mechanisms and therapeutic perspectivesFrederik Flindt Kreiner, Jordan M Kraaijenhof, Matthias von Herrath, et al.
Cardiovascular Drugs and Therapy|May 2, 2018
Correction to: Assessment of the 1% of Patients with Consistent < 15% Reduction in Low-Density Lipoprotein Cholesterol: Pooled Analysis of 10 Phase 3 ODYSSEY Alirocumab TrialsHarold E Bays, Robert S Rosenson, Marie T Baccara-Dinet, et al.
Cardiovascular Drugs and Therapy|May 5, 2020
Regional Variations in Alirocumab Dosing Patterns in Patients with Heterozygous Familial Hypercholesterolemia During an Open-Label Extension StudyGisle Langslet, G Kees Hovingh, John R Guyton, et al.
Journal of Lipid Research|November 14, 2021
LDL-C calculated by Friedewald, Martin-Hopkins, or NIH equation 2 versus beta-quantification: pooled alirocumab trialsHenry N Ginsberg, Robert S Rosenson, G Kees Hovingh, et al.
Journal of Clinical Pharmacology|September 10, 2011
Omeprazole impairs the absorption of mycophenolate mofetil but not of enteric-coated mycophenolate sodium in healthy volunteersM G Kees, T Steinke, S Moritz, et al.
International Journal of Antimicrobial Agents|April 25, 2012
Penetration of moxifloxacin into liver tissueChristoph Justinger, Martin K Schilling, Martin G Kees, et al.
British Journal of Clinical Pharmacology|March 27, 2015
Protein binding characteristics and pharmacokinetics of ceftriaxone in intensive care unit patientsMichael Schleibinger, Cathérine L Steinbach, Christoph Töpper, et al.
Lipids|October 5, 2014
Treatment of low HDL-C subjects with the CETP modulator dalcetrapib increases plasma campesterol only in those without ABCA1 and/or ApoA1 mutationsEric J Niesor, David Kallend, Darren Bentley, et al.
Atherosclerosis|July 18, 2016
Sequencing for LIPA mutations in patients with a clinical diagnosis of familial hypercholesterolemiaBarbara Sjouke, Joep C Defesche, Janine S E de Randamie, et al.
Pageof 38

Showing results (101-110 of 376) with videos related to

Sort By:
Pageof 38
Frontiers in Pharmacology|March 8, 2021
Neurocognitive Impairment After Propofol With Relevance for Neurosurgical Patients and Awake Craniotomies-A Prospective Observational StudyNina Zech, Milena Seemann, Ralf Luerding, et al.
Expert Review of Clinical Immunology|February 25, 2022
Interleukin 6 in diabetes, chronic kidney disease, and cardiovascular disease: mechanisms and therapeutic perspectivesFrederik Flindt Kreiner, Jordan M Kraaijenhof, Matthias von Herrath, et al.
Cardiovascular Drugs and Therapy|May 2, 2018
Correction to: Assessment of the 1% of Patients with Consistent < 15% Reduction in Low-Density Lipoprotein Cholesterol: Pooled Analysis of 10 Phase 3 ODYSSEY Alirocumab TrialsHarold E Bays, Robert S Rosenson, Marie T Baccara-Dinet, et al.
Cardiovascular Drugs and Therapy|May 5, 2020
Regional Variations in Alirocumab Dosing Patterns in Patients with Heterozygous Familial Hypercholesterolemia During an Open-Label Extension StudyGisle Langslet, G Kees Hovingh, John R Guyton, et al.
Journal of Lipid Research|November 14, 2021
LDL-C calculated by Friedewald, Martin-Hopkins, or NIH equation 2 versus beta-quantification: pooled alirocumab trialsHenry N Ginsberg, Robert S Rosenson, G Kees Hovingh, et al.
Journal of Clinical Pharmacology|September 10, 2011
Omeprazole impairs the absorption of mycophenolate mofetil but not of enteric-coated mycophenolate sodium in healthy volunteersM G Kees, T Steinke, S Moritz, et al.
International Journal of Antimicrobial Agents|April 25, 2012
Penetration of moxifloxacin into liver tissueChristoph Justinger, Martin K Schilling, Martin G Kees, et al.
British Journal of Clinical Pharmacology|March 27, 2015
Protein binding characteristics and pharmacokinetics of ceftriaxone in intensive care unit patientsMichael Schleibinger, Cathérine L Steinbach, Christoph Töpper, et al.
Lipids|October 5, 2014
Treatment of low HDL-C subjects with the CETP modulator dalcetrapib increases plasma campesterol only in those without ABCA1 and/or ApoA1 mutationsEric J Niesor, David Kallend, Darren Bentley, et al.
Atherosclerosis|July 18, 2016
Sequencing for LIPA mutations in patients with a clinical diagnosis of familial hypercholesterolemiaBarbara Sjouke, Joep C Defesche, Janine S E de Randamie, et al.
Pageof 38